CB issuance reduced to 2B KRW, 4.79% dilution
애드바이오텍
179530
Signal Score
Historical Avg Return (5d)
+0.00%
Data Coverage
100%n=2755
Risk-adjusted indicator based on 2755 historical DART filings. For informational purposes only — not investment advice.
Financial Impact
NEUTRAL
Key Numbers
- • Convertible Bond (CB) Total Amount (Amended): 2,000,000,000 KRW (Previously 3,000,000,000 KRW)
- • Conversion Price (Amended): 2,021 KRW/Share (Previously 1,992 KRW/Share)
- • Shares to be Issued upon Conversion (Amended): 989,609 Shares (Previously 1,506,024 Shares)
- • Dilution Rate (Amended): 4.79% of total shares (Previously 7.11%)
- • Funds Purpose: Acquisition of other corporate securities
AI Analysis Summary
ADBIOTECH Co.,Ltd. announced an amendment to its convertible bond (CB) issuance. The total CB amount has been reduced from 3 billion KRW to 2 billion KRW, with the conversion price adjusted upwards from 1,992 KRW/share to 2,021 KRW/share. This results in a lower potential dilution of 4.79% (989,609 shares) compared to the original 7.11% (1,506,024 shares). The funds are intended for acquiring other corporate securities. While the reduction in issuance size and dilution is positive, the overall impact remains neutral as it is still a dilutive event.
How This Event Is Evaluated
Capital Raise Evaluation
Capital raise events are evaluated by estimating dilution pressure, funding purpose, pricing terms, and impact on existing shareholders.
AI is used to interpret disclosures and extract structured data.
Signal scores are generated using event-specific methodologies and quantitative models.
- Potential dilution rate
- Issuance or conversion price
- Funding purpose
- Shareholder value impact
This content is for informational purposes only and does not constitute investment advice. Past signal patterns do not guarantee future results. All data is sourced from public DART filings.